Shares of Oculis Holding AG (NASDAQ:OCSAW – Get Free Report) were up 0.2% during trading on Monday . The company traded as high as $5.03 and last traded at $4.49. Approximately 13,348 shares were traded during mid-day trading, an increase of 109% from the average session volume of 6,380 shares. The stock had previously closed at $4.48.
Oculis Stock Performance
The company has a 50 day simple moving average of $13.37 and a two-hundred day simple moving average of $13.58.
Oculis Company Profile
Oculis SA is a clinical‐stage biopharmaceutical company focused on developing disease‐modifying therapies for serious eye diseases. Utilizing its proprietary ocular formulation technologies, the company is advancing a pipeline of small‐molecule product candidates designed for topical or injectable delivery. Lead programs include OCS-01, a topical eye drop candidate for diabetic macular edema, and OCS-02, targeting diabetic retinopathy. Oculis also has OCS-05 in development for optic neuropathies and other retinal disorders, reflecting its commitment to addressing a broad spectrum of unmet needs in ophthalmology.
Founded in 2016 and headquartered in Geneva, Switzerland, Oculis operates research and development facilities in Europe and the United States.
Featured Articles
- Five stocks we like better than Oculis
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
